Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Individuals ≥ 40 kg in weight with chronic genotype 1 or 2 HCV and HBV coinfection~* Individuals must not be taking or requiring treatment with HBV antiviral therapy at screening. For participants that are HBV treatment experienced, the most recent treatment must have been completed at least 6 months prior to Day 1.~* Cirrhosis determination by Fibroscan~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female or male is of childbearing potential~Key Exclusion Criteria:~* Current or prior history of clinically-significant illness or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~* Pregnant or nursing female~* Infection with human immunodeficiency virus (HIV) or hepatitis delta virus (HDV)~* Hepatocellular carcinoma (HCC) or other malignancy~* Current or prior history of clinical hepatic decompensation~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (Type: EXPERIMENTAL): LDV/SOF FDC for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).